Lucid Diagnostics Inc reports results for the quarter ended June 30 - Earnings Summary

Lucid Diagnostics

12/08/2026 23:22

Lucid Diagnostics Inc LUCD.OQ reported a quarterly adjusted loss of 8 cents​​ per share for the quarter ended June 30, identical to the same quarter last year.  The mean expectation of five analysts for the quarter was for a loss of 7 cents per share. Wall Street expected results to range from -8 cents to -6 cents per share.
Revenue rose 26.7% to $1.47 million from a year ago; analysts expected $1.44 million. 
Lucid Diagnostics Inc's reported EPS for the quarter was a loss of 8 cents​.
The company reported a quarterly loss of $14.72 million.
Lucid Diagnostics Inc shares had fallen by 10.2% this quarter and lost 11.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 6.4% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy" 
Wall Street's median 12-month price target for Lucid Diagnostics Inc is $3.00, about 67.2% above its last closing price of $0.98
This summary was machine generated from LSEG data August 12 at 10:22 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.07
-0.08
Missed
Mar. 31 2026 
-0.08
-0.17
Missed
Dec. 31 2025 
-0.10
-0.10
Met
Sep. 30 2025 
-0.11
-0.10
Beat